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Received March 30, 2016; accepted August 2, 2016AbstractBackground: Patients with severe motor and intellectual disabilities (SMID) are those who have both severe intellectual disabilities and severe
physical disabilities. Intractable epilepsy is often associated with SMID. The purpose of this study was to elucidate the relationship between
epilepsy associated with SMID and oxidative stress, and to clarify the safety and efficacy of the newer antiepileptic drugs (newer AEDs),
lamotrigine and levetiracetam.
Methods: This study was conducted in 27 SMID patients with epilepsy who were treated with the newer AEDs. The patient characteristics and
the safety and efficacy of the newer AEDs were investigated. The reactive oxygen metabolite (d-ROM) and biological antioxidant potential
(BAP) levels were measured as indicators of the degree of oxidative stress. The relationship between the investigation results (the patient
characteristics, and the safety and efficacy of the newer AEDs) and the results of measurements of the d-ROMs/BAP were analyzed.
Results: All the patients who discontinued the newer AEDs had abnormal plasma d-ROM levels. In addition, all the patients who developed
adverse events also had abnormal d-ROM levels. Furthermore, there was a trend toward a lower response rate in patients with higher plasma d-
ROM levels.
Conclusion: The results of this study suggested that d-ROM levels are useful for predicting the safety and efficacy of the newer AEDs
(lamotrigine, levetiracetam) in SMID patients with intractable epilepsy. Therefore, d-ROMs could be important biomarkers for determining the
safety and efficacy of drug therapy in SMID patients with epilepsy.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The disease entity of severe motor and intellectual dis-
abilities (SMID) is characterized by the presence of both se-
vere intellectual disabilities and severe physical disabilities,
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).concepts of “profound intellectual and multiple disabilities”
(PIMD)1 and “profound and multiple learning disabilities”
(PMLD).2
There are an estimated 40,000e50,000 SMID patients in
Japan.3 SMID is a condition in which the central nervous
system is damaged during the developmental stages in the
perinatal period and infancy, and the primary disease or
symptoms do not bate with age. In a previous study, we
demonstrated a statistically significant association between
SMID and epilepsy, which suggests that epilepsy is one of the
characteristic manifestations of SMID.4 Although the older
antiepileptic drugs (older AEDs) have long been used in drug
therapy for epilepsy in Japan, newer antiepileptic drugs (newersevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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market one after another since 2006. However, there have been
few reports exclusively addressing the efficacy of these drugs
against epilepsy associated with SMID. Furthermore, although
Tanuma et al5 conducted an investigation on the relationship
of SMID with respiratory disturbance and oxidative stress
based on measurement of plasma 8-hydroxy-20-deoxy-
guanosine (8-OHdG), there are no reports of studies on the
relationship between epilepsy associated with SMID and
oxidative stress. Therefore, we conducted this study to clarify
the usefulness and safety of the newer AEDs for epilepsy in
patients with SMID using oxidative stress markers, namely,
the oxidative stress [plasma levels of reactive oxygenTable 1
Background of patients (n¼ 27).
Sex Male 20 (70.8)
Female 7 (29.2)
Age (y) Average± SD 27.0± 7.3
Maximum 39
Minimum 10
Median 27.0
Main disease Cerebral palsy 12 (44.4)
Hypoxia encephalopathic
aftereffects
3 (11.1)
Epileptic encephalopathy
aftereffects
3 (11.1)
Cerebral hemorrhage
aftereffects
2 (7.4)
Lissencephaly 2 (7.4)
CFC syndrome 1 (3.7)
Acute encephalopathic
aftereffects
1 (3.7)
Theophylline encephalopathic
aftereffects
1 (3.7)
Meningitis aftereffects 1 (3.7)
Dentatorubral-pallidoluysian
atrophy
1 (3.7)
Renal damage Available 0
None 27
Liver damage Available 0
None 27
Comorbiditiesa Available 0
None 27
The number of use AEDs 1 agent 0 (0.0)
2 agents 1 (3.7)
3 agents 12 (44.4)
4 agents 12 (44.4)
5 agents  2 (7.4)
Use of old AEDsb Valproate sodium (VPA) 21 (32.3)
Phenobarbital (PB) 8 (12.3)
Zonisamide (ZNS) 8 (12.3)
Phenytoin (PHT) 6 (9.2)
Clonazepam (CZP) 6 (9.2)
Carbamazepine (CBZ) 5 (7.7)
Clobazam (CLB) 4 (6.2)
Ethosuximide (ESM) 3 (4.6)
Nitrazepam (NZP) 2 (3.1)
Clorazepete dipotassium 1 (1.5)
Acetazolamide 1 (1.5)
Data are presented as n or n (%).
AEDs¼ antiepileptic drugs; CFC¼ cardio-facio-cutaneous; SD¼ standard
deviation.
a Hypertension, diabetes, hyperlipidemia, kidney disease, infectious disease.
b There is overlap in a value (n ¼ 65).metabolites (d-ROMs)] and antioxidant activity [biological
antioxidant potential (BAP)] levels.
2. Methods2.1. PatientsAmong the SMID patients who were hospitalized and
treated at the Japanese Red Cross Tokushima Hinomine
Rehabilitation Center for People with Disabilities, Tokushima,
Japan between January 1, 2009 and December 31, 2015, 27
who manifested epilepsy and had been initiated on treatment
with the newer AEDs were included in this study. After
obtaining consent from the parents for this clinical study,
random samples were collected from these patients.2.2. Drugs evaluatedTwo drugs, lamotrigine (LTG) and levetiracetam (LEV),6,7
which are AEDs that received approval for use in Japan in
and after 2006 and are highly recommended worldwide, were
evaluated as the newer AEDs. AEDs that had received approval
for clinical use prior to 2006 were defined as the older AEDs.2.3. Items investigatedMedical records were investigated to collect the following
characteristics of the patients: sex, age, primary disease, having
organ disorder, and the number and types of used AEDs.Table 2
Continuation rate and safety of LTG and LEV.
Drug continuation rate LTG LEV
No. of cases 11 16
Withdrawal No. of cases
(Withdrawal reason)
2 (18.2) 3 (18.8)
Safety (adverse event)
Drug rash 1 (9.1) 0
Mood change/edema 0 1 (6.3)
Exacerbation of the seizure 0 1 (6.3)
Efficacy
Seizure No. of times immutability 1 (9.1) 1 (6.3)
Adverse eventa LTG LEV
No. of cases of the adverse event expression 2 (18.2) 4 (25.0)
No. of cases of the adverse event expression
(total) (Contents of adverse events)
2 (18.2) 5 (31.2)
Psychiatric disorders
Mood change 0 1 (6.3)
Nervous system disorders
Exacerbation of the seizure 0 1 (6.3)
Somnolence 1 (9.1) 2 (12.5)
Skin & subcutaneous tissue disorders
Drug rash 1 (9.1) 2 (12.5)
General disorders and administration
site conditions
Edema 0 1 (6.3)
Data are presented as n or n (%).
LEV¼ levetiracetam; LTG ¼ lamotrigine.
a Withdrawal number of cases by adverse event: LTG 1 (9.1%), LEV 2
(12.5%).
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Fig. 1. Change in the 6-month epilepsy seizure number of times prior to and after new AED addition. (A) LTG þ LEV. (B) LTG. (C) LEV. AED¼ antiepileptic
drug; LEV¼ levetiracetam; LTG ¼ lamotrigine.
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sons for drug discontinuation and incidence and details of
adverse events were investigated. Changes in the number of
epileptic seizures and overall improvement from 6 months
before to 6 months after addition of the newer AEDs were
investigated as the primary efficacy endpoints. The overall
improvement was assessed as follows: (1) marked improve-
ment: response rate 75%; (2) improvement: response rate
< 75% but  25%; (3) no change: response rate < 25%; (4)
aggravation: increase in the number of epileptic seizures after
addition of the newer AEDs.2.4. Items measuredBlood samples were collected from the patients prior to
breakfast and prior to administration of the drug (at 6 AM), but
not during or immediately after epileptic seizures or duringany infection. In those cases, blood was drawn the next time as
noted above. Additionally, blood was drawn approximately 1
week prior to and approximately 6 months after the addition of
newer AEDs. The blood samples were centrifuged at 1500g
for 10 minutes using the Table-top centrifuge model 2410
(Kubota Corporation, Tokyo, Japan) to separate the plasma.
The heparinized plasma samples were measured for the
following items using a free-radical analyzer (FREE CARRIO
DUO; Diacron International, Grosseto, Italy).
2.4.1. Measurement of the oxidative stress level (d-ROMs
test)
Twenty microliters of plasma was added to pH 4.8 buffer in
a cuvette and mixed by inversion (Fe2þ and Fe3þ were sepa-
rated from the blood proteins) to allow the Fe2þ and Fe3þ
radicals to catalyze the degradation of hydroperoxides in the
blood into alkoxyl and peroxy radicals. Next, 20 mL of a
A LTG + LEV
(B) LTG
(C) LEV
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Fig. 2. The overall improvement degree. (A) LTG þ LEV. (B) LTG. (C) LEV. LEV¼ levetiracetam; LTG ¼ lamotrigine.
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added to the solution, so that the free radicals oxidized the
chromogen substrate to yield red-colored radical cations.
Then, the solution was mixed by inverting, and the cuvette was
placed in a photometer for optical measurement at 505 nm.
2.4.2. Measurement of the antioxidant activity (BAP test)
Fifty microliters of a chromogen for BAP (Fe3þ-containing
reagent) was added to the cuvette to make the solution red.
After mixing the solution by inversion, the color density was
measured by photometry. Next, 10 mL of plasma was added to
the cuvette and mixed. Thereafter, the cuvette was placed in a
thermostat, and the reaction was allowed to proceed for 5
minutes. Finally, the cuvette was placed in a photometer for
optical measurement at 505 nm.
In a physically unimpaired person, normal d-ROMs values
are < 320 U.CARR, and normal BAP values are > 2000 mmol/L. Accordingly, we adopted these standard values, and those
values outside the normal range were defined as abnormal.2.5. Statistical analysisThe relationship between the data obtained on the safety
and efficacy of the newer AEDs and the measured d-ROM and
BAP values was analyzed. The statistical analysis software
IBM SPSS Statistics, version 21, was used. The two-sided
level of significance was set at 5%, and p < 0.05 was consid-
ered as indicative of a significant difference between the two.2.6. Ethical considerationsThis study was conducted with the approval of the Ethics
Committee of the Japanese Red Cross Tokushima Hinomine
Rehabilitation Center for People with Disabilities. As it is
Table 3
Measurement evaluation standard value of d-ROMs test and BAP test and the
result before and after LTG, LEV addition. (A) d-ROMs test, (B) BAP test.a
Evaluation Standard valueb Results
Before After
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written explanation was given to the families of the SMID
patients and their consent was obtained.
3. Resultsd-ROMs test
Normal range 250e300 2 (7.4) 5 (18.5)3.1. Patient characteristics
Border range 301e320 2 (7.4) 1 (3.7)
Low-level oxidative stress 321e340 3 (11.1) 5 (18.5)
Intermediate level oxidative stress 341e400 4 (14.8) 5 (18.5)
High-level oxidative stress 401e500 11 (40.7) 5 (18.5)
Very high-level oxidative stress >500 5 (18.5) 6 (22.2)
BAP test
Normal range >2200 19 (70.4) 18 (66.7)
Border range 2000e2200 7 (25.9) 8 (29.6)
Slight lack state 1800e1999 0 0
Lack state 1600e1799 0 0
Severe lack state 1400e1599 1 (3.7) 1 (3.7)
Very severe lack state <1400 0 0
Data are presented as n (%).In regards to patient sex, males were proportionally higher,
and the mean age of the patients was 27.0 ± 7.3 years.
Regarding the main disease entity, cerebral palsy was the most
common. The patient characteristics are shown in Table 1.
Overall, there were no patients with liver or renal damage,
and in all SMIDs, there was C-reactive protein (CRP) in
0.03e0.33 mg/dL. Concerning the number of AEDs adminis-
tered per patient,  80% of the patients were treated with three
or four AEDs, and valproate sodium was the most frequent
concomitantly used older AED.BAP¼ biological antioxidant potential; d-ROM¼ reactive oxygen metabo-
lites; LEV¼ levetiracetam; LTG ¼ lamotrigine.
a3.2. Drug continuation rate and adverse events
Comparing before and after LTG, LEV addition, the d-ROM values
decreased in predominance statistically after addition (paired t test, p> 0.01),
whereas BAP values did not a change (paired t test, p ¼ 0.97)
b Unit: d-ROMs, U.CARR; BAP, mmol/L.The drug continuation rate is shown in Table 2. The adverse
events were mild and improved with discontinuation of the
drug. All adverse events were mild and improved spontane-
ously without treatment.3.3. Changes in the number of epileptic seizures and
overall improvement from 6 months before to 6 months
after addition of the newer AEDsThree patients could not take it continuously and were
excluded. The results are shown in Figure 1.
The number of epileptic seizures significantly decreased
after the addition of the newer AEDs ( p< 0.01). Analysis by
drug showed that both LTG ( p¼ 0.01) and LEV ( p< 0.01)
significantly reduced the number of seizures.
The mean new AED response rate to the newer AEDs was
49.0%, and analysis by drug showed that the mean response
rates to LTG and LEV were 37.9% and 56.9%, respectively.
The overall improvement is shown in Figure 2.
The criteria for assessment of the overall improvement
were defined as follows: (1) marked improvement: response
rate  75%; (2) improvement: response rate < 75% but 
25%; (3) no change: response rate < 25%; (4) aggravation:
increased in the number of seizures after addition of the newer
AEDs.
When “marked improvement” and “improvement” were
defined as “effective,” the newer AEDs were effective in
83.3% of the patients. Analysis by drug also showed that LTG
and LEV were effective in 80.0% and 85.7% of the patients,
respectively.3.4. d-ROMs and BAP valuesThe criteria for evaluation of d-ROMs and BAP and the
measurement results prior to and after the newer AEDs addi-
tion are shown in Table 3 and Figure 3. d-ROMs values wereas follows: normal values were “before” 4 (14.8%) “after” 6
(22.2%), and abnormal values were “before” 23 (85.2%)
“after” 21 (77.8%).
BAP values: anteroposterior no change, normal values were
26 (96.3%), abnormal value alone was 1 (3.7%). When
distributed an oxidation stress degree were evaluated, d-ROM
values decreased only in the high-level oxidative stress group.3.5. Relationship between the continuation rate and
plasma d-ROM levelsComparative analysis between patients with normal and
abnormal plasma d-ROM levels revealed that although there
were no significant differences between the two groups
( p¼ 0.55), all patients with adverse events had abnormal
plasma d-ROM levels. In particular, in both individuals who
discontinued the newer AEDs not because of adverse events
but because of a lack of efficacy, the oxidative stress levels
were very high. The results of the analysis are shown in
Figure 4A.3.6. Relationship between adverse events and the plasma
levels of d-ROMsComparative analysis between patients with normal and
abnormal plasma d-ROM levels revealed that although there
were no significant differences between the two groups
( p¼ 0.28), all patients with adverse events had abnormal plasma
d-ROM levels. In particular, one participant who discontinued
the newer AEDs owing to the development of seizure aggrava-
tion as an adverse event showed a very high level of oxidative
stress. The results of the analysis are shown in Figure 4B.
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Fig. 3. Change of the d-ROM level prior to and after the new AED addition (paired t test). (AeD) Comparison was done according to an oxidation stress category.
In (B) the high-level oxidative stress group (d-ROM 401e500), a d-ROM level decreased in predominance. In the other patient groups, there were few changes.
AED¼ antiepileptic drug; d-ROM¼ reactive oxygen metabolite.
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and plasma d-ROM levelsThe results of the analysis are shown in Figure 5.
The findings revealed a trend toward a lower response rate
in patients with higher plasma d-ROM levels. All three pa-
tients who were assessed as having seizure aggravation/no
change in the seizure activity, and discontinued the newer
AEDs that showed very high levels of oxidative stress.
4. Discussion
Because epilepsy associated with SMID is intractable,
multiple AEDs tend to be used simultaneously. Although
concomitant use of multiple AEDs certainly has an effect on
the seizure activity, it is associated with several problems: (1)
it cannot be identified as to which AED is effective; (2) the
higher incidence of adverse events leads to a decrease in the
quality of life. In particular, because SMID patients cannot
express themselves, they cannot complain of the adverse
events that they are experiencing. Therefore, AEDs with highsafety and efficacy, and development of objective indicators to
predict the clinical course after drug administration are
required.
As compared to the older AEDs, the newer AEDs that were
recently approved have different mechanisms of action [LTG:
inhibition of N-type Ca2þ channels and inhibition of glutamate
release; LEV: binding to synaptic vesicle protein 2A (SV2A)
to modulate neurotransmitters] and have characteristics that
are substantially different from those of the older AEDs, in
that the frequency of adverse events and efficacy are inde-
pendent of the blood drug concentrations.
Analysis of the 6-month newer AED continuation rate
revealed that, as compared to general epilepsy patients re-
ported in previous studies, the LTG continuation rate was
higher (81.8% vs. 65e70%8,9) and the LEV continuation rate
was somewhat lower (81.2% vs. 92.2%10) in our patients,
suggesting that the newer AEDs can be continued for a longer
period even in SMID patients with epilepsy.
Analysis of the safety of the newer AEDs revealed that as
compared to patients with general epilepsy in drug use-results
surveys, the incidence of adverse events associated with LTG
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Fig. 4. Relations of (A) continuation rate, (B) adverse event, and the d-ROM values (Fisher’s exact test). d-ROM¼ reactive oxygen metabolite.
25M. Morimoto et al. / Journal of the Chinese Medical Association 80 (2017) 19e28was somewhat lower (18.2% vs. 21.9%11), and the incidence
of adverse events associated with LEV was somewhat higher
(25.0% vs. 13.7%12) in our patients. However, in the present
study, there were no serious adverse events, and all the adverse
events resolved spontaneously without treatment. Based on
these findings, the newer AEDs, in general, can be said to be
highly safe even in SMID patients with epilepsy. However,
dizziness, for example, which occurs at a high incidence in
patients taking these drugs, is detected based on the patient’s
own complaints; therefore, its incidence cannot be determined
in SMID patients as these patients cannot express themselves
or report the symptoms that they are experiencing. Thus,
predictors of such adverse events are required in SMID pa-
tients receiving drug treatment.
Analysis of the efficacy of the newer AEDs for epilepsy
associated with SMID revealed that the addition of the newerAEDs generally decreased the number of epileptic seizures.
This is speculated to be attributable to the differing mecha-
nisms of action of the newer AEDs as compared to the older
AEDs.
In clinical practice, oxidative stress markers are used in
various ways, and the frequently used marker 8-OHdG, which
is measured in the urine, shows diurnal variations.13 However,
SMID patients cannot pass urine spontaneously, and it is
difficult to collect urine samples from these patients. However,
because the plasma d-ROM levels can be measured rapidly at
a fixed time using micro blood samples (30 mL) collected from
the fingertip in a minimally invasive manner, plasma d-ROM
levels are considered a useful marker of oxidative stress in
SMID patients.
Plasma levels of oxidative stress markers increase with
age.13,14 In addition, comorbidities (hypertension, diabetes,
Regression line r = -0.558851  P < 0.01
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Fig. 5. Relation of the effectiveness (Response rate) and d-ROMs level. (A) Relation between d-ROM values and BAP values. (B) Distribution of d-ROMs/BAP.
BAP¼ biological antioxidant potential; d-ROMs¼ reactive oxygen metabolites.
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d-ROM levels.15e17 Comparisons with healthy individuals
matched for age13,14 revealed that the plasma levels of d-
ROMs were higher in our patients than in healthy individuals.
Analysis of comorbidities also revealed that none of the par-
ticipants had any factors affecting the plasma d-ROM levels in
the present study, and that the high plasma d-ROM levels were
likely to be caused by the epileptic seizures in the SMID
patients.
In addition, in regard to the BAP values, carnitine
replacement therapy is used for hypocarnitinemia associated
with high-dose valproate sodium treatment or tube feeding in
SMID patients with epilepsy.18,19 Carnitine is known as an
antioxidant, and carnitine administration has been reported to
increase the expression of superoxide dismutase, catalase,
glutathione peroxidase, etc.,20 which may lead to maintenance
of the antioxidant activity.
We compared d-ROMs and BAP values, prior to and after
the newer AEDs addition.
The d-ROMs values decreased in predominance after
addition, but the BAP values did not change. LTG and LEV do
not have the chemical structure to provide radical removal
such as edaravone. Therefore, it is believed that the d-ROM
values might decrease because seizure decreased arising from
the newer AEDs dosage.
In Figure 3, seizure number of times and d-ROM values did
not change in the Very high-level oxidative stress group.
However, in the High-level oxidative stress group, attack
number of times and d-ROM values decreased. Thus, progress
of newer AEDs may suppose the measurement of d-ROMs
prior to the addition of newer AEDs.
The d-ROM values were different in each patient. However,
the BAP values showed similar levels. In this study, it is
thought that the internal antioxidant capacity of the SMIDepilepsy patient remained. The d-ROMs/BAP ratio was not
substantially changed and depended on the d-ROM values
(Fig. 6). We paid attention to the d-ROM value. In the safety
assessment of the newer AEDs through analysis of the drug
continuation rate and incidence of adverse events, all patients
who discontinued the newer AEDs or developed adverse events
had abnormal plasma d-ROM levels. All adverse events were
mild. Why do adverse events tend to occur in patients with high
plasma d-ROM levels? There have been no studies using
oxidative stress markers to reliably predict the adverse events
of drugs, and the detailed underlying mechanisms are un-
known. However, it has been reported that high preoperative
plasma d-ROM levels increase the risk of complications after
cardiac surgery,21 and that mutations or increased expression of
oxidative stress-related genes increase the risk of development
of adverse effects of the drugs.22 Furthermore, it was also re-
ported that a glycation marker, pentosidine, which is an indi-
cator of aging as well as of oxidation, is an effective predictor
of cisplatin cytotoxicity and renal dysfunction.23 Therefore,
measurement of the plasma d-ROM levels prior to the start of
treatment allows the probability of adverse events to be pre-
dicted, thereby increasing the possibility of early detection of
adverse events. We think that the plasma d-ROM levels could
be very useful as a predictive marker, especially in SMID pa-
tients who cannot express what they are feeling.
Various studies have reported that LTG and LEV exert
neuroprotective and anti-inflammatory effects.24e27 Therefore,
it was investigated using electron spin resonance as to whether
LTG and LEV possess free-radical scavenging activity, and the
results revealed that neither drug had any free-radical scav-
enging activity, suggesting that LTG and LEV per se do not
reduce oxidative stress in vivo.
The d-ROMs test measures the concentration of hydroper-
oxides generated by free radicals. Hydroperoxides are known
Fig. 6. (A) Relation between d-ROMs value and BAP value and (B) distribution of d-ROMs/BAP. BAP¼ biological antioxidant potential; d-ROM¼ reactive
oxygen metabolite.
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presence of metal ions, and are therefore not only oxidative
stress markers, but also, possibly, free-radical amplifiers.28
Accordingly, hydroperoxides may be responsible for the in-
crease in the incidence of adverse events and decrease in theseizure-suppressive effect of the newer AEDs in the presence
of high levels of oxidative stress.
Hydroperoxides are generated by reactions between their
precursors, peroxy radicals, and unsaturated fatty acids. These
reactions can be inhibited by the peroxy radical trapping
28 M. Morimoto et al. / Journal of the Chinese Medical Association 80 (2017) 19e28activity of vitamin E.29 Therefore, it has been suggested that
prior administration of vitamin E could reduce the plasma
levels of d-ROMs and increase the safety and seizure-
suppressive effect of LTG and LEV in patients with
extremely high plasma d-ROM levels. Vitamin C is also
widely known as an antioxidant vitamin; however, water-
soluble vitamin C is likely to be poorly effective, because
hydroperoxides are lipophilic.
The limitations of this study were the insufficient number
of measurements/analyses owing to the small total number of
patients classified as having SMID. We think that it is
necessary to carry out a study with a larger number of cases of
SMID patients with epilepsy in the future. Another future task
is to carry out the investigation in patients with PIMD and
PMLD, the pathogenetic backgrounds of which are similar to
the pathogenesis of SMID.
Our study findings suggested that plasma d-ROM levels
may serve as an important biomarker for individualized drug
therapy of epilepsy in patients with SMID.
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